GlassScriptPhysician profile
Floyd Buen
NPI 1902291479
$1,582.52
in general payments reported to CMS, 2019-2025
15 companies · $243 in 2025
The $243 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $95.62 · 2021: $368 · 2022: $362 · 2023: $311 · 2024: $202 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $756.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $656.47 | 2020-2025 | |
| Inspire Medical Systems, INC. | $167.97 | 2024-2025 | Inspire |
| Intersect Ent, INC. | $146.67 | 2021 | |
| Stryker Corporation | $111.72 | 2020-2023 | Audion Et Dilation System |
| Genzyme Corporation | $101.96 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $86.70 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $78.48 | 2022-2025 | Nucala |
| Smith+Nephew, INC. | $58.04 | 2024-2025 | Halo, Tula |
| Aroa Biosurgery Incorporated | $33.80 | 2022 | |
| Boston Scientific Corporation | $29.93 | 2023 | Bodyguardian |
| Biohaven Pharmaceutical Holding Company LTD. | $26.14 | 2022 | |
| Integra Lifesciences Corporation | $22.92 | 2022 | |
| Aerin Medical INC. | $22.35 | 2024 | |
| Hikma Pharmaceuticals USA | $21.11 | 2023 | Ryaltris |
| Neurent Medical Limited | $18.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Floyd Buen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.